{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:15Z","timestamp":1740108315394,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"DOI":"10.1007\/s00228-022-03440-w","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:02:45Z","timestamp":1672898565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Testosterone treatment and the risk of osteonecrosis: a pharmacovigilance analysis in Vigibase"],"prefix":"10.1007","author":[{"given":"Cl\u00e9mentine","family":"Vabre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-2392","authenticated-orcid":false,"given":"Kyle","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-8126","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Vezzosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriana H.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-9579","authenticated-orcid":false,"given":"Christel","family":"Renoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"3440_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.5694\/mja13.10111","volume":"199","author":"DJ Handelsman","year":"2013","unstructured":"Handelsman DJ (2013) Global trends in testosterone prescribing, 2000\u20132011: expanding the spectrum of prescription drug misuse. Med J Aust 199:548\u2013551. https:\/\/doi.org\/10.5694\/mja13.10111","journal-title":"Med J Aust"},{"key":"3440_CR2","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.juro.2016.10.063","volume":"197","author":"PK Rao","year":"2017","unstructured":"Rao PK, Boulet SL, Mehta A, Hotaling J, Eisenberg ML, Honig SC et al (2017) Trends in testosterone replacement therapy use from 2003 to 2013 among reproductive-age men in the United States. J Urol 197:1121\u20131126. https:\/\/doi.org\/10.1016\/j.juro.2016.10.063","journal-title":"J Urol"},{"key":"3440_CR3","unstructured":"Research CFDEA (2019) FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. FDA"},{"key":"3440_CR4","volume-title":"The risk of cardiovascular events in men receiving testosterone therapy","author":"C Chase","year":"2014","unstructured":"Chase C (2014) The risk of cardiovascular events in men receiving testosterone therapy. An Endocrine Society statement, Endocrine Society"},{"key":"3440_CR5","doi-asserted-by":"publisher","first-page":"e2127349","DOI":"10.1001\/jamanetworkopen.2021.27349","volume":"4","author":"A Everhart","year":"2021","unstructured":"Everhart A, Harper K, Jeffery MM, Levin Z, Morden NE, Sankar A et al (2021) Trends in testosterone prescriptions for older men enrolled in commercial insurance and medicare advantage. JAMA Netw Open 4:e2127349\u2013e2127349. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.27349","journal-title":"JAMA Netw Open"},{"key":"3440_CR6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamainternmed.2018.6505","volume":"179","author":"NE Morden","year":"2019","unstructured":"Morden NE, Woloshin S, Brooks CG, Schwartz LM (2019) Trends in testosterone prescribing for age-related hypogonadism in men with and without heart disease. JAMA Intern Med 179:446\u2013448. https:\/\/doi.org\/10.1001\/jamainternmed.2018.6505","journal-title":"JAMA Intern Med"},{"key":"3440_CR7","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.3928\/01477447-20151120-03","volume":"38","author":"CJ Glueck","year":"2015","unstructured":"Glueck CJ, Riaz R, Prince M, Freiberg RA, Wang P (2015) Testosterone therapy can interact with thrombophilia, leading to osteonecrosis. Orthopedics 38:e1073\u2013e1078. https:\/\/doi.org\/10.3928\/01477447-20151120-03","journal-title":"Orthopedics"},{"key":"3440_CR8","doi-asserted-by":"publisher","unstructured":"Glueck CJ, Goldenberg N, Wang P (2018) Testosterone therapy, thrombophilia, venous thromboembolism, and thrombotic events. J Clin Med Res 8. https:\/\/doi.org\/10.3390\/jcm8010011","DOI":"10.3390\/jcm8010011"},{"key":"3440_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.therap.2017.08.006","volume":"73","author":"J-L Faillie","year":"2018","unstructured":"Faillie J-L (2018) Case-non case studies: principles, methods, bias and interpretation. Therapie 73:247\u2013255. https:\/\/doi.org\/10.1016\/j.therap.2017.08.006","journal-title":"Therapie"},{"key":"3440_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S2213-8587(19)30382-1","volume":"8","author":"R Pradhan","year":"2020","unstructured":"Pradhan R, Montastruc F, Rousseau V, Patorno E, Azoulay L (2020) Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis. Lancet Diabetes Endocrinol 8:13\u201314. https:\/\/doi.org\/10.1016\/S2213-8587(19)30382-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3440_CR11","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.amjmed.2019.03.022","volume":"132","author":"SY Loo","year":"2019","unstructured":"Loo SY, Azoulay L, Nie R, Dell\u2019Aniello S, Yu OHY, Renoux C (2019) Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort study. Am J Med 132:1069-1077.e4. https:\/\/doi.org\/10.1016\/j.amjmed.2019.03.022","journal-title":"Am J Med"},{"key":"3440_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5968","volume":"355","author":"C Martinez","year":"2016","unstructured":"Martinez C, Suissa S, Rietbrock S, Katholing A, Freedman B, Cohen AT et al (2016) Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ 355:i5968. https:\/\/doi.org\/10.1136\/bmj.i5968","journal-title":"BMJ"},{"key":"3440_CR13","unstructured":"AbbVie (2021) Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) study. clinicaltrials.gov"},{"key":"3440_CR14","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","volume":"103","author":"S Bhasin","year":"2018","unstructured":"Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM et al (2018) Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103:1715\u20131744. https:\/\/doi.org\/10.1210\/jc.2018-00229","journal-title":"J Clin Endocrinol Metab"},{"key":"3440_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/andr.12770","volume":"8","author":"G Corona","year":"2020","unstructured":"Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G et al (2020) European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology 8:970\u2013987. https:\/\/doi.org\/10.1111\/andr.12770","journal-title":"Andrology"},{"key":"3440_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5694\/mja16.00393","volume":"205","author":"BB Yeap","year":"2016","unstructured":"Yeap BB, Grossmann M, McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ et al (2016) Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Med J Aust 205:173\u2013178. https:\/\/doi.org\/10.5694\/mja16.00393","journal-title":"Med J Aust"},{"key":"3440_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/cen.14633","volume":"96","author":"CN Jayasena","year":"2022","unstructured":"Jayasena CN, Anderson RA, Llahana S, Barth JH, MacKenzie F, Wilkes S et al (2022) Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol 96:200\u2013219. https:\/\/doi.org\/10.1111\/cen.14633","journal-title":"Clin Endocrinol"},{"key":"3440_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12178-015-9277-8","volume":"8","author":"KN Shah","year":"2015","unstructured":"Shah KN, Racine J, Jones LC, Aaron RK (2015) Pathophysiology and risk factors for osteonecrosis. Curr Rev Musculoskelet Med 8:201\u2013209. https:\/\/doi.org\/10.1007\/s12178-015-9277-8","journal-title":"Curr Rev Musculoskelet Med"},{"key":"3440_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/jim-2017-000637","volume":"66","author":"CJ Glueck","year":"2018","unstructured":"Glueck CJ, Goldenberg N, Wang P (2018) Thromboembolism peaking 3 months after starting testosterone therapy: testosterone-thrombophilia interactions. J Investig Med 66:733\u2013738. https:\/\/doi.org\/10.1136\/jim-2017-000637","journal-title":"J Investig Med"},{"key":"3440_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1076029613485154","volume":"20","author":"CJ Glueck","year":"2014","unstructured":"Glueck CJ, Richardson-Royer C, Schultz R, Burger T, Labitue F, Riaz MK et al (2014) Testosterone, thrombophilia, and thrombosis. Clin Appl Thromb Hemost 20:22\u201330. https:\/\/doi.org\/10.1177\/1076029613485154","journal-title":"Clin Appl Thromb Hemost"},{"key":"3440_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7326\/0003-4819-137-1-200207020-00008","volume":"137","author":"KD Miller","year":"2002","unstructured":"Miller KD, Masur H, Jones EC, Joe GO, Rick ME, Kelly GG et al (2002) High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 137:17\u201325. https:\/\/doi.org\/10.7326\/0003-4819-137-1-200207020-00008","journal-title":"Ann Intern Med"},{"key":"3440_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4158\/EP09288.CR","volume":"17","author":"N Kaviani","year":"2011","unstructured":"Kaviani N, Bukberg P, Manessis A, Yen V, Young I (2011) Iatrogenic osteoporosis, bilateral HIP osteonecrosis, and secondary adrenal suppression in an HIV-infected man receiving inhaled corticosteroids and ritonavir-boosted highly active antiretroviral therapy. Endocr Pract 17:74\u201378. https:\/\/doi.org\/10.4158\/EP09288.CR","journal-title":"Endocr Pract"},{"key":"3440_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12878-017-0076-x","volume":"17","author":"MI Jarman","year":"2017","unstructured":"Jarman MI, Lee K, Kanevsky A, Min S, Schlam I, Mahida C et al (2017) Case report: primary osteonecrosis associated with thrombophilia-hypofibrinolysis and worsened by testosterone therapy. BMC Hematol 17:5. https:\/\/doi.org\/10.1186\/s12878-017-0076-x","journal-title":"BMC Hematol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03440-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03440-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03440-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T17:06:22Z","timestamp":1673197582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03440-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":23,"alternative-id":["3440"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03440-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"assertion":[{"value":"14 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this is an observational pharmacovigilance study, review from an ethics committee is not necessary, as stated by the French law [D\u00e9cret n\u00b0 2016-1537].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Because all data in VigiBase is anonymized, patient informed consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}